<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lupin Limited — News on 6ix</title>
<link>https://6ix.com/company/lupin-limited</link>
<description>Latest news and press releases for Lupin Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 13:13:17 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lupin-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364d1378dffbe2df153f95.webp</url>
<title>Lupin Limited</title>
<link>https://6ix.com/company/lupin-limited</link>
</image>
<item>
<title>Press Release Apr 22 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-apr-22-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-apr-22-2026-8</guid>
<pubDate>Wed, 22 Apr 2026 13:13:17 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated April 22, 2026, titled "Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States".</description>
</item>
<item>
<title>Press Release Apr 10 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-apr-10-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-apr-10-2026-5</guid>
<pubDate>Fri, 10 Apr 2026 23:49:39 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated April 10, 2026, titled "Lupin Launches Dapagliflozin Tablets in the United States".</description>
</item>
<item>
<title>Press Release Apr 08 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-apr-08-2026-10</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-apr-08-2026-10</guid>
<pubDate>Wed, 08 Apr 2026 21:20:47 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated April 08, 2026, titled "Lupin Announces Approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States ".</description>
</item>
<item>
<title>Press Release Apr 07 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-apr-07-2026-13</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-apr-07-2026-13</guid>
<pubDate>Wed, 08 Apr 2026 01:21:18 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Lupin Announces the Approval of Dapagliflozin Tablets in the United States".</description>
</item>
<item>
<title>Press Release Apr 02 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-apr-02-2026-14</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-apr-02-2026-14</guid>
<pubDate>Thu, 02 Apr 2026 14:58:18 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated April 02, 2026, titled "Lupin Completes Acquisition of VISUfarma".</description>
</item>
<item>
<title>Lupin Completes Acquisition of VISUfarma</title>
<link>https://6ix.com/company/lupin-limited/news/lupin-completes-acquisition-of-visufarma</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/lupin-completes-acquisition-of-visufarma</guid>
<pubDate>Thu, 02 Apr 2026 07:00:00 GMT</pubDate>
<description>Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin's strategy to expand its specialty care portfolio and strengthen its presence in Europe.</description>
</item>
<item>
<title>Press Release Mar 31 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-mar-31-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-mar-31-2026-5</guid>
<pubDate>Tue, 31 Mar 2026 12:28:39 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated March 31, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection".</description>
</item>
<item>
<title>Press Release Mar 25 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-mar-25-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-mar-25-2026-2</guid>
<pubDate>Wed, 25 Mar 2026 13:16:18 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated March 25, 2026, titled "Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets".</description>
</item>
<item>
<title>Press Release Mar 19 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-mar-19-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-mar-19-2026-3</guid>
<pubDate>Thu, 19 Mar 2026 12:15:59 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Lupin Manufacturing Solutions Announces Expansion of Manufacturing Facility at Dabhasa, India".</description>
</item>
<item>
<title>Press Release Mar 17 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-mar-17-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-mar-17-2026-3</guid>
<pubDate>Tue, 17 Mar 2026 16:05:06 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India".</description>
</item>
<item>
<title>Lupin Ranks No. 1 Globally in Pharma; Tops All Sectors in India in S&P ESG Assessment 2025</title>
<link>https://6ix.com/company/lupin-limited/news/lupin-ranks-no-1-globally-in-pharma-tops-all-sectors-in-india-in-sandp-esg-assessment-2025</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/lupin-ranks-no-1-globally-in-pharma-tops-all-sectors-in-india-in-sandp-esg-assessment-2025</guid>
<pubDate>Fri, 06 Mar 2026 09:42:00 GMT</pubDate>
<description>Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced its recognition among the top 1% of companies worldwide in the S&P Global Corporate Sustainability Assessment (CSA). Lupin attained a score of 91 out of 100, establishing itself as the leading pharmaceutical company globally, and the leader across all sectors in India, surpassing both Indian and international peers.</description>
</item>
<item>
<title>Press Release Feb 27 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-27-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-27-2026-3</guid>
<pubDate>Fri, 27 Feb 2026 18:00:28 GMT</pubDate>
<description>Lupin Limited has submitted a press release dated February 27, 2026, regarding receipt of Establishment Inspection Report (EIR) by the Company from the U.S. FDA for its facility in Goa, India.</description>
</item>
<item>
<title>Press Release (Revised) Feb 26 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-revised-feb-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-revised-feb-26-2026</guid>
<pubDate>Fri, 27 Feb 2026 01:42:16 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a revised press release dated February 26, 2026, titled "Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans".</description>
</item>
<item>
<title>Press Release Feb 26 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-26-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-26-2026-2</guid>
<pubDate>Fri, 27 Feb 2026 00:56:05 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated February 26, 2026, titled "Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans".</description>
</item>
<item>
<title>Press Release Feb 24 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-24-2026</guid>
<pubDate>Wed, 25 Feb 2026 00:13:05 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States".</description>
</item>
<item>
<title>Lupin Announces the Approval and Launch of Brivaracetam Oral Solution in the United States</title>
<link>https://6ix.com/company/lupin-limited/news/lupin-announces-the-approval-and-launch-of-brivaracetam-oral-solution-in-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/lupin-announces-the-approval-and-launch-of-brivaracetam-oral-solution-in-the-united-states</guid>
<pubDate>Tue, 24 Feb 2026 18:09:00 GMT</pubDate>
<description>Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact® Oral Solution, 10 mg/mL, of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Following the approval, the company initiated the launc</description>
</item>
<item>
<title>Press Release Feb 23 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-23-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-23-2026-2</guid>
<pubDate>Mon, 23 Feb 2026 20:27:17 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated February 23, 2026, titled "Lupin Receives European Commission Approval for Biosimilar Ranibizumab".</description>
</item>
<item>
<title>Press Release Feb 16 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-16-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-16-2026-1</guid>
<pubDate>Mon, 16 Feb 2026 21:00:06 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated February 16, 2026, titled "Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex in Canada".</description>
</item>
<item>
<title>Press Release Feb 13 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-13-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-13-2026-3</guid>
<pubDate>Sat, 14 Feb 2026 00:50:02 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated February 13, 2026, titled "Anand Kripalu Joins Lupin Board as Independent Director ".</description>
</item>
<item>
<title>Press Release Feb 12 2026</title>
<link>https://6ix.com/company/lupin-limited/news/press-release-feb-12-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/lupin-limited/news/press-release-feb-12-2026-5</guid>
<pubDate>Fri, 13 Feb 2026 03:39:46 GMT</pubDate>
<description>Lupin Limited has informed the Exchange regarding a press release dated February 12, 2026, titled "Lupin Q3 FY2026 Results".</description>
</item>
</channel>
</rss>